U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Endometrial Serous Adenocarcinoma

MedGen UID:
1371726
•Concept ID:
C4331226
•
Neoplastic Process
Synonym: Recurrent Uterine Corpus Serous Carcinoma

Definition

The reemergence of endometrial serous adenocarcinoma after a period of remission. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRecurrent Endometrial Serous Adenocarcinoma

Professional guidelines

PubMed

Uterine serous carcinoma: key advances and novel treatment approaches.
Ferriss JS, Erickson BK, Shih IM, Fader AN
Int J Gynecol Cancer 2021 Aug;31(8):1165-1174. Epub 2021 Jul 1 doi: 10.1136/ijgc-2021-002753. PMID: 34210768
Controversies in the Management of Early-stage Serous Endometrial Cancer.
Larish A, Mariani A, Langstraat C
In Vivo 2021 Mar-Apr;35(2):671-680. doi: 10.21873/invivo.12307. PMID: 33622859Free PMC Article
Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies.
Lee EK, Fader AN, Santin AD, Liu JF
Gynecol Oncol 2021 Jan;160(1):322-332. Epub 2020 Nov 5 doi: 10.1016/j.ygyno.2020.10.017. PMID: 33160694

Recent clinical studies

Etiology

Ovarian preservation in gynecologic oncology: current indications and techniques.
Bizzarri N, Pavone M, Loverro M, Querleu D, Fagotti A, Scambia G
Curr Opin Oncol 2023 Sep 1;35(5):401-411. Epub 2023 Jul 13 doi: 10.1097/CCO.0000000000000969. PMID: 37498120
Uterine serous carcinoma: key advances and novel treatment approaches.
Ferriss JS, Erickson BK, Shih IM, Fader AN
Int J Gynecol Cancer 2021 Aug;31(8):1165-1174. Epub 2021 Jul 1 doi: 10.1136/ijgc-2021-002753. PMID: 34210768
Uterine serous carcinoma.
Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Enomoto T, Takehara K, Denys H, Nout RA, Lorusso D, Vaughan MM, Bini M, Takano M, Provencher D, Indini A, Sagae S, Wimberger P, Póka R, Segev Y, Kim SI, Candido Dos Reis FJ, Lopez S, Mariani A, Leitao MM Jr, Raspagliesi F, Panici PB, Di Donato V, Muzii L, Colombo N, Scambia G, Pignata S, Monk BJ
Gynecol Oncol 2021 Jul;162(1):226-234. Epub 2021 Apr 30 doi: 10.1016/j.ygyno.2021.04.029. PMID: 33934848Free PMC Article
Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis.
Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers S, Secord AA, Havrilesky L, O'Malley DM, Backes FJ, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi K, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD
Clin Cancer Res 2020 Aug 1;26(15):3928-3935. Epub 2020 Jun 29 doi: 10.1158/1078-0432.CCR-20-0953. PMID: 32601075Free PMC Article
Endometrial cancer.
Greven KM, Corn BW
Curr Probl Cancer 1997 Mar-Apr;21(2):65-127. doi: 10.1016/s0147-0272(97)80002-5. PMID: 9128804

Diagnosis

Uterine serous carcinoma.
Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Enomoto T, Takehara K, Denys H, Nout RA, Lorusso D, Vaughan MM, Bini M, Takano M, Provencher D, Indini A, Sagae S, Wimberger P, Póka R, Segev Y, Kim SI, Candido Dos Reis FJ, Lopez S, Mariani A, Leitao MM Jr, Raspagliesi F, Panici PB, Di Donato V, Muzii L, Colombo N, Scambia G, Pignata S, Monk BJ
Gynecol Oncol 2021 Jul;162(1):226-234. Epub 2021 Apr 30 doi: 10.1016/j.ygyno.2021.04.029. PMID: 33934848Free PMC Article
HER2 Testing and Reporting in Endometrial Serous Carcinoma: Practical Recommendations for HER2 Immunohistochemistry and Fluorescent In Situ Hybridization: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting.
Buza N
Int J Gynecol Pathol 2021 Jan;40(1):17-23. doi: 10.1097/PGP.0000000000000711. PMID: 33290351
HER2 Testing in Endometrial Serous Carcinoma: Time for Standardized Pathology Practice to Meet the Clinical Demand.
Buza N
Arch Pathol Lab Med 2021 Jun 1;145(6):687-691. doi: 10.5858/arpa.2020-0207-RA. PMID: 32649220
Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis.
Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers S, Secord AA, Havrilesky L, O'Malley DM, Backes FJ, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi K, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD
Clin Cancer Res 2020 Aug 1;26(15):3928-3935. Epub 2020 Jun 29 doi: 10.1158/1078-0432.CCR-20-0953. PMID: 32601075Free PMC Article
Endometrial cancer.
Greven KM, Corn BW
Curr Probl Cancer 1997 Mar-Apr;21(2):65-127. doi: 10.1016/s0147-0272(97)80002-5. PMID: 9128804

Therapy

Uterine serous carcinoma.
Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Enomoto T, Takehara K, Denys H, Nout RA, Lorusso D, Vaughan MM, Bini M, Takano M, Provencher D, Indini A, Sagae S, Wimberger P, Póka R, Segev Y, Kim SI, Candido Dos Reis FJ, Lopez S, Mariani A, Leitao MM Jr, Raspagliesi F, Panici PB, Di Donato V, Muzii L, Colombo N, Scambia G, Pignata S, Monk BJ
Gynecol Oncol 2021 Jul;162(1):226-234. Epub 2021 Apr 30 doi: 10.1016/j.ygyno.2021.04.029. PMID: 33934848Free PMC Article
HER2 Testing and Reporting in Endometrial Serous Carcinoma: Practical Recommendations for HER2 Immunohistochemistry and Fluorescent In Situ Hybridization: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting.
Buza N
Int J Gynecol Pathol 2021 Jan;40(1):17-23. doi: 10.1097/PGP.0000000000000711. PMID: 33290351
HER2 Testing in Endometrial Serous Carcinoma: Time for Standardized Pathology Practice to Meet the Clinical Demand.
Buza N
Arch Pathol Lab Med 2021 Jun 1;145(6):687-691. doi: 10.5858/arpa.2020-0207-RA. PMID: 32649220
Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis.
Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers S, Secord AA, Havrilesky L, O'Malley DM, Backes FJ, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi K, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD
Clin Cancer Res 2020 Aug 1;26(15):3928-3935. Epub 2020 Jun 29 doi: 10.1158/1078-0432.CCR-20-0953. PMID: 32601075Free PMC Article
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.
Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers SK, Secord AA, Havrilesky L, O'Malley DM, Backes F, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi KS, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD
J Clin Oncol 2018 Jul 10;36(20):2044-2051. Epub 2018 Mar 27 doi: 10.1200/JCO.2017.76.5966. PMID: 29584549

Prognosis

Extrauterine Mesonephric-like Carcinoma: A Comprehensive Single Institution Study of 33 Cases.
Euscher ED, Marques-Piubelli ML, Ramalingam P, Wistuba I, Lawson BC, Frumovitz M, Malpica A
Am J Surg Pathol 2023 Jun 1;47(6):635-648. Epub 2023 Apr 6 doi: 10.1097/PAS.0000000000002039. PMID: 37026792
Uterine serous carcinoma: key advances and novel treatment approaches.
Ferriss JS, Erickson BK, Shih IM, Fader AN
Int J Gynecol Cancer 2021 Aug;31(8):1165-1174. Epub 2021 Jul 1 doi: 10.1136/ijgc-2021-002753. PMID: 34210768
Uterine serous carcinoma.
Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Enomoto T, Takehara K, Denys H, Nout RA, Lorusso D, Vaughan MM, Bini M, Takano M, Provencher D, Indini A, Sagae S, Wimberger P, Póka R, Segev Y, Kim SI, Candido Dos Reis FJ, Lopez S, Mariani A, Leitao MM Jr, Raspagliesi F, Panici PB, Di Donato V, Muzii L, Colombo N, Scambia G, Pignata S, Monk BJ
Gynecol Oncol 2021 Jul;162(1):226-234. Epub 2021 Apr 30 doi: 10.1016/j.ygyno.2021.04.029. PMID: 33934848Free PMC Article
Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis.
Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers S, Secord AA, Havrilesky L, O'Malley DM, Backes FJ, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi K, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD
Clin Cancer Res 2020 Aug 1;26(15):3928-3935. Epub 2020 Jun 29 doi: 10.1158/1078-0432.CCR-20-0953. PMID: 32601075Free PMC Article
Endometrial cancer.
Greven KM, Corn BW
Curr Probl Cancer 1997 Mar-Apr;21(2):65-127. doi: 10.1016/s0147-0272(97)80002-5. PMID: 9128804

Clinical prediction guides

HER2 in uterine serous carcinoma: Current state and clinical perspectives.
Navarro Sanchez JM, Finkelman BS, Turner BM, Katerji H, Wang X, Varghese S, Wang T, Peng Y, Hicks DG, Zhang H
Am J Clin Pathol 2023 Oct 3;160(4):341-351. doi: 10.1093/ajcp/aqad056. PMID: 37267036
Extrauterine Mesonephric-like Carcinoma: A Comprehensive Single Institution Study of 33 Cases.
Euscher ED, Marques-Piubelli ML, Ramalingam P, Wistuba I, Lawson BC, Frumovitz M, Malpica A
Am J Surg Pathol 2023 Jun 1;47(6):635-648. Epub 2023 Apr 6 doi: 10.1097/PAS.0000000000002039. PMID: 37026792
Molecular analysis of endometrial serous carcinoma reveals distinct clinicopathologic and genomic subgroups.
Lin DI, Fine A, Danziger NA, Huang RSP, Mata DA, Decker B, Killian JK, Ramkissoon SH, Lechpammer M, Janovitz T, Ross JS, Sokol ES, Elvin JA
Gynecol Oncol 2022 Mar;164(3):558-565. Epub 2022 Jan 5 doi: 10.1016/j.ygyno.2021.12.030. PMID: 34998597
Minimal uterine serous carcinoma and endometrial polyp: a close clinicopathological relationship.
Assem H, Rottmann D, Finkelstein A, Wang M, Ratner E, Santin AD, Buza N, Hui P
Hum Pathol 2021 Dec;118:1-8. Epub 2021 Sep 8 doi: 10.1016/j.humpath.2021.09.001. PMID: 34508766
Controversies in the Management of Early-stage Serous Endometrial Cancer.
Larish A, Mariani A, Langstraat C
In Vivo 2021 Mar-Apr;35(2):671-680. doi: 10.21873/invivo.12307. PMID: 33622859Free PMC Article

Recent systematic reviews

Minimally invasive surgery versus open surgery in high-risk histologic endometrial cancer patients: A meta-analysis.
Kim NR, Lee AJ, Yang EJ, So KA, Lee SJ, Kim TJ, Shim SH
Gynecol Oncol 2022 Aug;166(2):236-244. Epub 2022 Jun 17 doi: 10.1016/j.ygyno.2022.06.004. PMID: 35725657
Comparison of minimally invasive surgery with laparotomic approach in the treatment of high risk endometrial cancer: A systematic review.
Scaletta G, Dinoi G, Capozzi V, Cianci S, Pelligra S, Ergasti R, Fagotti A, Scambia G, Fanfani F
Eur J Surg Oncol 2020 May;46(5):782-788. Epub 2019 Dec 2 doi: 10.1016/j.ejso.2019.11.519. PMID: 31818527
Comparative safety and effectiveness of robot-assisted laparoscopic hysterectomy versus conventional laparoscopy and laparotomy for endometrial cancer: A systematic review and meta-analysis.
Park DA, Lee DH, Kim SW, Lee SH
Eur J Surg Oncol 2016 Sep;42(9):1303-14. Epub 2016 Jun 29 doi: 10.1016/j.ejso.2016.06.400. PMID: 27439723

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...